MAGEA4 and neoplasm: To address this issue, Sanderson and colleagues developed an in vitro extensive preclinical testing protocol to evaluate the safety and efficacy of an affinity-enhanced MAGE-A4-specific TCR by using a wide range of testing material, including human tumor cell lines, primary tumor material, and panels of EBV-transformed B-lymphoblastic cell lines (B-LCLs) expressing multiple HLA alleles and molecular analysis [130].